Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Current Assets: 2022-2025

  • Abivax's Current Assets fell 62.75% to $97.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $97.5 million, marking a year-over-year decrease of 62.75%. This contributed to the annual value of $182.4 million for FY2024, which is 40.73% down from last year.
  • As of Q2 2025, Abivax's Current Assets stood at $97.5 million, which was down 30.16% from $139.6 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Current Assets ranged from a high of $307.7 million in Q4 2023 and a low of $36.9 million during Q4 2022.
  • Its 3-year average for Current Assets is $197.7 million, with a median of $182.4 million in 2024.
  • In the last 5 years, Abivax's Current Assets skyrocketed by 733.54% in 2023 and then tumbled by 62.75% in 2025.
  • Over the past 4 years, Abivax's Current Assets (Quarterly) stood at $36.9 million in 2022, then soared by 733.54% to $307.7 million in 2023, then crashed by 40.73% to $182.4 million in 2024, then crashed by 62.75% to $97.5 million in 2025.
  • Its Current Assets stands at $97.5 million for Q2 2025, versus $139.6 million for Q1 2025 and $182.4 million for Q4 2024.